Multiple predicted cardiovascular and inflammatory targets

The term Multiple predicted cardiovascular and inflammatory targets does not refer to a single, discrete molecular entity such as a specific receptor or enzyme. Instead, it serves as a categorical descriptor for a broad array of proteins and signaling pathways that intersect at the junction of heart disease and immune system activation. In modern drug discovery, particularly within systems biology and computational modeling, this designation is used to describe compounds (like statins or colchicine) that exert therapeutic effects by interacting with various targets including cytokines, adhesion molecules, and intracellular kinases (Libby, P., 2021, Nature) [1]. Because this entry encompasses a diverse range of biological structures—such as G protein-coupled receptors, enzymes, and transcription factors—it lacks a unique UniProt identifier or a specific canonical classification. Consequently, it is considered an incorrect or overly broad target name for structured biochemical databases, as it represents a therapeutic strategy or a multi-target profile rather than a single point of pharmacological intervention (Ridker, P. M., 2017, NEJM) [2].

Other names

Cardiovascular and inflammatory target clusterPredicted multi-target profilePleiotropic cardiovascular targets

This entry represents a collective grouping of various molecular targets rather than a single mechanism of action. It typically refers to the polypharmacological profile of drugs that modulate multiple pathways simultaneously to treat complex diseases.